Summary
Gilead Sciences, Inc. (GILD) filed an 8-K/A on July 17, 2009, to amend a previous 8-K filing dated July 16, 2009. The amendment addresses a minor typographical error in the amount Gilead agreed to pay Tibotec Pharmaceuticals under a License and Collaboration Agreement. The agreement, related to the development of TMC-278, was initially reported with an incorrect payment figure. This amendment clarifies that Gilead will pay up to €71,450,000 for Tibotec’s development costs for TMC-278, correcting a previous misstatement of the amount.
Key Highlights
- 1Amendment to a material definitive agreement filed on July 16, 2009.
- 2The amendment corrects a typographical error in the payment amount related to a License and Collaboration Agreement with Tibotec Pharmaceuticals.
- 3The agreement involves the development of TMC-278.
- 4Gilead will pay Tibotec up to €71,450,000 for development costs of TMC-278.
- 5The original filing incorrectly stated the payment amount.
- 6The correction ensures accurate reporting of the financial commitment to the TMC-278 development program.
- 7The filing was made by Robin L. Washington, Senior Vice President and Chief Financial Officer.